- Home
- IBRX vs BIRK Comparison
IBRX vs BIRK Comparison
Compare IBRX & BIRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBRX | BIRK |
|---|---|---|
| Founded | 2014 | 1774 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 7.0B |
| IPO Year | 2015 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IBRX | BIRK |
|---|---|---|
| Price | $7.94 | $32.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $12.57 | ★ $61.43 |
| AVG Volume (30 Days) | ★ 10.9M | 2.4M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $13.71 |
| Revenue Next Year | $131.15 | $14.30 |
| P/E Ratio | ★ N/A | $17.48 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $31.33 |
| 52 Week High | $12.43 | $57.39 |
Technical Indicators
Market Signals| Indicator | IBRX | BIRK |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 35.27 |
| Support Level | $7.77 | N/A |
| Resistance Level | $8.51 | $42.11 |
| Average True Range (ATR) | 0.53 | 1.90 |
| MACD | 0.04 | -0.86 |
| Stochastic Oscillator | 62.50 | 9.21 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.